Section 01
What it's used for
Blood Sugar Control in Diabetes
Approved as Mounjaro for type 2 diabetes. In the SURPASS 1-5 trials in people, it lowered HbA1c, a blood-sugar marker, by 1.9-2.4% and cut weight by 7-13 kg depending on dose. SURPASS-2 beat semaglutide 1 mg for blood sugar and weight loss.
▸Clinical wording
Tirzepatide is approved (Mounjaro) for glycemic control in type 2 diabetes. The SURPASS program (SURPASS 1-5) demonstrated unprecedented HbA1c reductions of 1.9-2.4% and weight loss of 7-13 kg depending on dose. SURPASS-2 showed superiority over semaglutide 1mg for both glycemic control and weight loss.
Long-Term Weight Loss
Approved as Zepbound (2023) for adults with obesity, or overweight plus a health condition. In SURMOUNT-1, the 15 mg dose cut body weight by 20.9% on average, with 57% losing at least 20%; SURMOUNT-2 confirmed benefit in type 2 diabetes.
▸Clinical wording
Tirzepatide is approved as Zepbound (2023) for adults with obesity or overweight with comorbidities. In the SURMOUNT-1 trial, the 15mg dose produced a mean body weight reduction of 20.9%, with 57% of participants achieving at least 20% weight loss; SURMOUNT-2 confirmed efficacy in patients with obesity and type 2 diabetes.
Obstructive Sleep Apnea
In the SURMOUNT-OSA human trial, it cut breathing interruptions during sleep, the apnea-hypopnea index, by up to 63% from baseline, and improved blood oxygen and sleep quality. This use has been submitted to regulators for approval.
▸Clinical wording
The SURMOUNT-OSA trial demonstrated significant reduction in apnea-hypopnea index (AHI) — up to 63% reduction from baseline — along with improvements in oxygen saturation and sleep quality, leading to regulatory submissions for this indication.
Heart Failure With Obesity
In the SUMMIT human trial, people with obesity and a heart-failure form where the heart pumps normally but fills poorly had fewer symptoms, better exercise ability, and lower NT-proBNP, a strain marker, beyond weight loss alone.
▸Clinical wording
The SUMMIT trial showed tirzepatide significantly improved heart failure symptoms, exercise capacity, and reduced NT-proBNP in HFpEF patients with obesity, suggesting direct cardioprotective effects beyond weight reduction.
Fatty Liver Disease (MASH)
In the SYNERGY-NASH human trial, the liver disease MASH, fatty liver with inflammation, resolved in 44-62% of patients by dose, with significant improvement in liver scarring, called fibrosis. Now under regulatory review.
▸Clinical wording
The SYNERGY-NASH trial demonstrated resolution of MASH in 44-62% of patients across dose groups, with significant fibrosis improvement. This indication is under regulatory review.
Kidney Disease in Diabetes
A look-back at the SURPASS trials found it cut a urine marker of kidney damage, the albumin-to-creatinine ratio, by 19.3-26.3% in people with type 2 diabetes, suggesting kidney protection. No trial has tested polycystic kidney disease yet.
▸Clinical wording
A pooled post hoc analysis of the SURPASS 1-5 trials found tirzepatide reduced urinary albumin-to-creatinine ratio by 19.3% to 26.3% in participants with type 2 diabetes, supporting a renoprotective effect in diabetic kidney disease. No dedicated clinical trial of tirzepatide in polycystic kidney disease has been conducted; published material on GLP-1 receptor agonists in this condition is limited to rationale and preclinical papers stating that further clinical studies are required.
Section 02
Mechanism of Action
Switching on two gut-hormone receptors
- It activates the receptors for two hormones the gut releases after eating (GIP and GLP-1).
- Those receptors drive the extra insulin release seen after swallowed glucose versus an intravenous drip.
- Adding the GIP receptor brings effects in tissues the GLP-1 receptor alone does not reach.
▸Clinical wording
Dual Incretin Receptor Agonism
Tirzepatide activates both the GIP receptor (GIPR) and GLP-1 receptor (GLP-1R), two class B G-protein coupled receptors that mediate the incretin effect — the enhanced insulin secretion observed after oral versus intravenous glucose. While GLP-1R agonism is well-established in diabetes treatment, the addition of GIPR agonism provides complementary metabolic benefits through distinct tissue-specific signaling pathways.
What the second gut receptor adds
- In the pancreas it strengthens insulin release when blood sugar is already raised.
- In fat tissue it improves storage under the skin and reduces fat deposited in the wrong places.
- In bone it supports bone-building cells, an effect GLP-1-only drugs do not share.
▸Clinical wording
GIP Receptor Signaling
GIPR activation in pancreatic beta cells potentiates glucose-stimulated insulin secretion through cAMP/PKA and Epac2 pathways, complementing GLP-1R effects. In adipose tissue, GIP signaling enhances lipid buffering capacity, improving triglyceride storage in subcutaneous adipose tissue and reducing ectopic lipid deposition. In bone, GIP receptor activation promotes osteoblast function — a unique benefit not shared by GLP-1R agonists.
Appetite, stomach speed and insulin
- This receptor drives insulin release only when glucose is raised, and suppresses the opposing hormone glucagon.
- It slows stomach emptying and dampens appetite through hunger-control neurons in the brain.
- Most of the appetite and digestive effects of tirzepatide come from this arm.
▸Clinical wording
GLP-1 Receptor Signaling
GLP-1R activation drives glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying, and central appetite suppression through hypothalamic POMC/CART neuron activation. The GLP-1 component is primarily responsible for the appetite-suppressive and gastrointestinal effects of tirzepatide.
Four routes that add up
- Appetite suppression and slowed stomach emptying come from the GLP-1 side.
- Better fat-tissue function and fat handling come from the GIP side.
- Brain and body signals combine to raise energy expenditure.
- Improved insulin sensitivity reduces the fat building driven by high insulin.
▸Clinical wording
Synergistic Weight Loss Mechanisms
The dual-agonist approach produces synergistic weight reduction through: (1) GLP-1R-mediated appetite suppression and gastric slowing, (2) GIP-mediated improvements in adipose tissue function and lipid metabolism, (3) enhanced energy expenditure through combined central and peripheral mechanisms, and (4) improved insulin sensitivity reducing hyperinsulinemia-driven lipogenesis.
Insulin-producing cells working better
- Standard indices of insulin-cell function (HOMA-B, disposition index) improve significantly.
- Both the fast first burst and the slower second phase of insulin release get stronger.
- Better glucose handling lowers the stress on insulin-producing cells.
▸Clinical wording
Beta Cell Function Enhancement
Tirzepatide significantly improves beta cell function as measured by HOMA-B and disposition index. Dual incretin signaling enhances both first and second phase insulin secretion while reducing beta cell stress through improved glucose handling.
Section 03
Biological Pathways
- cAMP/PKA/CREBGIPR and GLP-1R signal through Gαs-mediated cAMP. In beta cells, PKA phosphorylates SNAP-25 and Munc13-1 to potentiate insulin exocytosis; CREB drives insulin gene transcription and survival genes (Bcl-2, IRS-2).
- PI3K/Akt/mTORDual receptor activation amplifies PI3K/Akt, promoting beta cell survival, glucose uptake, and suppression of hepatic gluconeogenesis; mTOR contributes to beta cell hypertrophy and secretory capacity.
- AMPK/PGC-1α energy metabolismIn skeletal muscle and adipose tissue, tirzepatide activates AMPK, enhancing mitochondrial biogenesis and fatty acid oxidation; PGC-1α upregulation improves oxidative capacity and energy expenditure.
- Wnt/β-catenin in boneGIPR activation uniquely engages Wnt/β-catenin signaling in osteoblasts, promoting bone formation and potentially mitigating bone loss from major weight loss, distinguishing tirzepatide from pure GLP-1R agonists.
Section 04
Dosage Information
Tyr-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-Aib-Leu-Asp-Lys-Ile-Ala-Gln-Lys(C20 fatty diacid)-Ala-Phe-Val-Gln-Trp-Leu-Ile-Ala-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser| Route / system | Context | Range studied | Limitation |
|---|---|---|---|
| Subcutaneous — type 2 diabetes label | Mounjaro, FDA prescribing information | 2.5 mg weekly for 4 weeks, then +2.5 mg at intervals of 4 weeks or more; ceiling 15 mg, 10 mg from age 10 — 28–214 µg/kg at 70–90 kg | The 15 mg is a ceiling reached after at least 20 weeks of steps, not a starting dose, and this label approves it for blood sugar, not weight loss. |
| Subcutaneous — obesity and sleep apnea | Zepbound, FDA label; apnea must be moderate to severe | 2.5 mg weekly for 4 weeks, then +2.5 mg every 4 weeks or more; maintenance 5, 10 or 15 mg weekly, and only 10 or 15 mg for apnea | Label entry was BMI 30, or 27 with a weight illness. The 2.5 mg is a start; the maintenance numbers come after months of steps. Nausea 25–28%, vomiting 8–13%. |
| Subcutaneous — phase 3 trial | Obesity, 72 weeks | 5, 10 and 15 mg weekly, each reached over 20 weeks of steps; mean weight change at week 72: −15.0%, −19.5%, −20.9% vs −3.1% on placebo | No group started at the maintenance dose; all got diet and activity advice. In a later trial, people moved to placebo at 36 weeks regained 14.0% by week 88. |
| Subcutaneous — compounded, grey-market | Dosed in syringe units, not from a labeled pen | No fixed strength. 30 mg in 3 mL gives 10 mg/mL, so 2.5 mg is 25 units on a U-100 syringe; at 5 mg/mL it is 50, at 20 mg/mL 12.5. | Units measure volume, not drug: the number belongs to the vial, not to tirzepatide. By April 2025 the FDA had about 480 reports of doses 5–20 times too high. |
Results
Syringe Fill Level (100u syringe)
Set positive values for: Recommended dose per kg.
Research Use Only. This information is for educational and research purposes only. Not intended for medical advice or self-medication.
Section 05
Protocols
- Protocol 01
Tirzepatide Advanced Weight Loss
Superior dual GLP-1/GIP agonist for maximum weight loss. Achieves 4-12 lbs more loss than Semaglutide.
- Focus
- Weight Loss
- Level
- Advanced
- Duration
- 6+ months
Section 06
Stability & Storage
Storing the product
The pen or vial is kept refrigerated at 2–8 °C before first use, protected from light and not frozen. A lyophilised research-grade form is instead kept frozen at −20 °C for long-term storage and reconstituted with bacteriostatic water shortly before use. Single-dose pens deliver one fixed dose and are meant to be discarded after that use.
After opening
Once in use, the pen may be kept at room temperature up to 30 °C for up to 21 days, and a multi-dose pen is used within 21 days of first use. The reconstituted research-grade solution is kept at 2–8 °C and used within 28 days; repeated freeze-thaw cycles and temperatures above 30 °C are avoided for both forms.
Section 07
Side Effects & Precautions
Tirzepatide's side effects are dominated by gastrointestinal symptoms during dose escalation, plus several boxed and organ-specific warnings that define who should not use it.
Digestive and injection-site effects
- Nausea (12-33%), diarrhea (12-23%), and vomiting (5-13%) are the most common adverse effects, generally mild to moderate and decreasing with continued treatment.
- Decreased appetite (9-20%), constipation (6-11%), and dyspepsia (indigestion) are also common.
- Local injection-site reactions — redness, itching, swelling — occur in about 2-5% of patients and are typically mild and resolve on their own.
Gallbladder and pancreas events
- Gallstones (cholelithiasis) and gallbladder inflammation (cholecystitis) have been reported at rates of 0.5-1.5%, associated with rapid weight loss.
- Acute pancreatitis has been reported rarely; tirzepatide should not be used in patients with a history of pancreatitis.
Thyroid C-cell tumor warning
Based on rodent carcinogenicity studies, a boxed warning exists for thyroid C-cell tumors; clinical relevance in humans is unknown. It is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome.
Blood sugar and eye effects
- As monotherapy, hypoglycemia (low blood sugar) risk is low since the mechanism is glucose-dependent; risk rises when combined with insulin or sulfonylureas.
- Rapid improvements in blood glucose may temporarily worsen diabetic retinopathy (diabetes-related eye damage) in patients who already have it.
Section 08
Regulatory Status
The compounded version that once filled the gap during its shortage is no longer legal. WADA does not prohibit the molecule: it tracks tirzepatide markers on the Monitoring Program from 1 January 2026, and monitored substances carry no sanction.
FDA / United States
Approved for three separate indications
As Mounjaro, tirzepatide was approved in 2022 for type 2 diabetes at 5, 10, and 15 mg once weekly. As Zepbound, it was approved in 2023 for chronic weight management, in December 2024 for moderate-to-severe obstructive sleep apnea, and in early 2026 for metabolic dysfunction-associated steatohepatitis (MASH).
EMA / European Union
Approved; over 40 countries follow
The EMA has approved tirzepatide for the same core indications, and comparable national regulators in more than 40 countries have authorised it as well, making it one of the most widely approved peptide-based drugs on the market.
Compounding
No longer legal in the United States
The FDA declared the tirzepatide shortage resolved in late 2024; compounding grace periods for pharmacies expired in February and March 2025. In April 2026 the FDA proposed removing tirzepatide from the bulk-substances list altogether, closing even the narrow exceptions that remained.
WADA
On the Monitoring Program, not banned
Tirzepatide is banned for competing athletes at all times, in and out of competition, as a peptide hormone and metabolic modulator; its approved medical indications do not create a blanket exemption.
None of these approvals cover compounded, generic, or research-labelled tirzepatide sold outside the approved Mounjaro or Zepbound supply chain. Regulatory status differs between jurisdictions and changes over time; check the current documents of your own regulator before relying on any of this.
Section 09
Research Studies
- [1]LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of conceptCoskun T, Sloop KW, Loghin C, et al. · Molecular Metabolism · 2018
- [2]How May GIP Enhance the Therapeutic Efficacy of GLP-1?Samms RJ, Coghlan MP, Sloop KW. · Trends in Endocrinology & Metabolism · 2020
- [3]Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonistWillard FS, Douros JD, Gabe MB, et al. · JCI Insight · 2020
- [4]Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trialRosenstock J, Wysham C, Frias JP, et al. · The Lancet · 2021
- [5]Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2)Frias JP, Davies MJ, Rosenstock J, et al. · New England Journal of Medicine · 2021
- [6]Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1)Jastreboff AM, Aronne LJ, Ahmad NN, et al. · New England Journal of Medicine · 2022
- [7]Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 DiabetesHeise T, DeVries JH, Urva S, et al. · Diabetes Care · 2023
- [8]Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trialGarvey WT, Frias JP, Jastreboff AM, et al. · The Lancet · 2023
- [9]Tirzepatide Improved Markers of Islet Cell Function and Insulin Sensitivity in People With T2D (SURPASS-2)Frias JP, De Block C, Brown K, et al. · Journal of Clinical Endocrinology & Metabolism · 2024
- [10]Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity (SUMMIT)Packer M, Zile MR, Kramer CM, et al. · New England Journal of Medicine · 2025
Section 10
Frequently Asked Questions
In the SURPASS-2 head-to-head trial, tirzepatide showed superior glycemic control and greater weight loss than semaglutide 1 mg once weekly in people with type 2 diabetes. That comparison used semaglutide's diabetes dose, not the higher dose approved for weight loss, so it does not settle which drug loses more weight at their respective top doses.
In the 72-week SURMOUNT-1 obesity trial, mean weight loss was 15.0%, 19.5% and 20.9% across the three doses tested, versus 3.1% on placebo. Every dose group spent about 20 weeks stepping up before reaching its maintenance level, so the number at 72 weeks reflects months of gradual titration, not a quick result.
In a trial where participants were switched to placebo at week 36, they had regained 14.0% of body weight by week 88. The available data point to weight coming back once the drug is stopped.
Gastrointestinal effects dominate: nausea in 12 to 33% of patients, diarrhea in 12 to 23%, and vomiting in 5 to 13%, mostly during dose escalation. Gallbladder problems occur in 0.5 to 1.5% of patients, tied to rapid weight loss, and the label carries a boxed warning for thyroid C-cell tumors based on rodent studies, with human relevance still unknown.
No. GIP/GLP-1 dual receptor agonists are not on the WADA Prohibited List, and no therapeutic use exemption is required for tirzepatide. Since 2024 this drug class has been on WADA's monitoring program, where laboratories track patterns of use without imposing sanctions; whether to prohibit the class is a discussion aimed at the 2028 Games, not a current rule.
No — compounded product is measured in syringe units off a vial's concentration rather than delivered as a fixed pen dose, and that concentration varies by supplier (10 mg/mL, 5 mg/mL and 20 mg/mL all circulate). The FDA had logged roughly 480 reports by April 2025 of people receiving doses 5 to 20 times higher than intended because a unit count was read as if it meant the same thing across different vial strengths.
There is no published trial data on combining tirzepatide with retatrutide or other incretin therapies — the approved trials tested it against semaglutide, not alongside it or other GLP-1/GIP agents. Stacking two drugs that act on overlapping hormone receptors has not been studied for either safety or added benefit.